Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 6/20 | 0.32 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | BCL9 | O00512 | 1/20 | 0.30 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7562638 | 0.86 | REN (0.35) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7569542 | 0.84 | REN (0.48) | RENBCL9CTNNB1 | |
| SCHEMBL7544005 | 0.84 | REN (0.47) | REN | |
| SCHEMBL6042320 | 0.78 | REN (0.32) | REN | |
| SCHEMBL7554357 | 0.78 | P2RX3 (0.30) | — | |
| SCHEMBL6043103 | 0.77 | REN (0.49) | REN | |
| SCHEMBL7563846 | 0.75 | CYP3A4 (0.33) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7562108 | 0.75 | SLC6A4 (0.39) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6041300 | 0.73 | REN (0.35) | RENTACR1 | |
| SCHEMBL7561346 | 0.73 | SLC6A4 (0.38) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |